IL-ADTALEM
17.8.2020 08:02:09 CEST | Business Wire | Press release
ACAMS, in partnership with artificial intelligence (AI) company ElephantThink, has successfully conceptualized and delivered its first fully online web-based compliance training program for Dutch banking group ING. The training partnership is for a multi-lingual SaaS solution offering mobile and web-based access to equip recipients with core competencies required to perform analysis, onboarding and anti-money laundering prevention roles and considered pioneering in the world of financial crime prevention training.
ING, which has a presence in over 40 countries serving over 38 million customers, places great emphasis on compliance, know your customer (KYC) / customer due diligence (CDD) and enhanced due diligence (EDD), which is reflected in the 4-year training agreement with ACAMS and ElephantThink.
Under the terms of the partnership, training is delivered digitally via e-learning on the ElephantThink Smart Learning Platform, and accessible in nine languages - English, Dutch, French, German, Italian, Romanian, Spanish, Turkish and Polish. Learners will have the ability to access the web-based learning curriculum supported by a companion mobile application which includes gamification elements to drive engagement and information retention. Qualifying ING employees will receive a verifiable digital certificate upon completion of their training.
Commenting on the training partnership, Roel Louwhoff, chief operations officer and chief transformation officer of ING, said: “As a gatekeeper to the financial system, ING has a responsibility to protect it, our customers and society against financial and economic crimes. Partnering with ACAMS to introduce their internationally recognized and certified digital training enables us to further enhance the KYC knowledge, skills and expertise of our employees in an innovative and engaging manner. This helps to fight financial economic crime, ensuring our customers can continue banking safely and securely as we empower them to stay a step ahead in life and in business.’’
Angela Salter, Interim President of ACAMS, said, “This is our first foray into delivering global web-based training to the KYC / CDD and transaction monitoring (TM) teams, and the promise of accelerated reach and efficacy is especially significant in the current environment. The commitment of ING to support a revolutionary training approach for a highly regulated and constantly evolving operating landscape cemented the success of our ground-breaking partnership with ElephantThink.”
Jack Smies, CEO of ElephantThink, said, “The mix of very high quality content from our partner ACAMS combined with our capabilities on AI, gamification and digital claims can really turbo charge people’s learning, which is reflected in the initial response and results of the training.”
Under the terms of the partnership ACAMS will make available AML, Sanctions, KYC and Transaction Monitoring programmes as well as ACAMS Certified Know Your Customer Associate (CKYCA) training at foundational and intermediate levels. These trainings are available in English, Dutch and multiple other languages, providing front-line and operations teams with the tools to perform KYC, CDD and EDD duties. ING’s sanctions, AML compliance and audit team learners will also have access to the full suite of ACAMS courses for the 2nd and 3rd lines of defence, underpinned by ACAMS’ comprehensive continuous education and alerts programme.
In a separate development, ACAMS has been granted approval by the Netherlands training registry body CRKBO to provide anti-financial crime training on a VAT free basis in the country, representing a savings of 21% on every ACAMS training course procured direct from ACAMS including its gold-standard CAMSTM Certified AML Specialist and recently launched Certified Global Sanctions Specialist (CGSS) qualifications.
About ACAMS®
ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a leading workforce solutions provider headquartered in the United States. ACAMS is the largest international membership organization dedicated to enhancing the knowledge and skills of anti-money laundering (AML) and financial crime prevention professionals from a wide range of industries. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide. Its new Certified Global Sanctions Specialist (CGSS) certification commenced in January 2020. Visit acams.org for more information.
About Adtalem Global Education
The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal ) and LinkedIn .
About ElephantThink:
ElephantThink is an Artificial Intelligence company that focuses on algorithms and models. By applying this specifically to employee training and development they created a Smart Learning Platform. This smart learning platform can provide hyper personalization so that the learning is optimized for maximum efficiency per individual learner and is unique in that it adapts to the specific way each participant learns. By using spaced repetition of learning elements that are memory dependent, gamification to ensure user engagement and verifiable certificates and badges for user motivation and recognition ET is able to significantly improve the learner’s development. Visit elephantthink.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
